Cantargia Confident About Nadunolimab’s Prospects For Pancreatic Cancer
Swedish Biotech Raises Funds To Advance IL1RAP Inhibitor
The selection of nadulonimab by the Pancreatic Cancer Action Network for its adaptive clinical trial is a strong validation of the Stockholm-based firm's compound, which is also being evaluated for lung cancer.
You may also be interested in...
Leaving the validation of a drug target until the end of Phase III studies is risky, but working on the unvalidated targets identified by others is riskier still.
The Swiss firm's canakinumab has proved to be an effective treatment for several inflammation-driven rare conditions but disappointment from the CANOPY-2 trial suggests that cancer will follow cardiovascular as an indication where the therapy falls by the wayside.
The UK firm's ensifentrine has exceeded analyst expectations by cutting the rate of moderate to severe COPD exacerbations by 42% over 24 weeks.